Document is current
Any future updates will be listed below
-
Authors
Hakim, Seifeldin https://orcid.org/0000-0001-7898-9611
Ramireddy, Srinivas https://orcid.org/0000-0003-2989-3642
Amin, Mitual https://orcid.org/0000-0002-0558-2615
Gebara, Souheil https://orcid.org/0000-0002-0705-4330
Cappell, Mitchell S. https://orcid.org/0000-0003-3445-5428
- License Information
-
More Information
Article History
Received: 24 May 2018
Accepted: 9 August 2018
First Online: 28 August 2018
Compliance with ethical standards
:
: None. In particular, Dr. Cappell, as a consultant of the US Food and Drug Administration (FDA) Advisory Committee for Gastrointestinal Drugs, affirms that this paper does not discuss any proprietary confidential pharmaceutical data submitted to the FDA. Dr. Cappell is a member of the speaker’s bureau for AstraZeneca and Daiichi Sankyo, co-marketers of Movantik and has received a one-time consulting fee from Mallinckrodt. This work does not discuss any drug manufactured or marketed by AstraZeneca, Daiichi Sankyo, or Mallinckrodt.
: This study received approval from the IRB of William Beaumont Hospital at Royal Oak on July 28, 2017.
